[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Angiero F, Mellone P, Baldi A, Stefani M: Osteoblastoma of the jaw: report of two cases and review of the literature. In Vivo; 2006 Sep-Oct;20(5):665-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteoblastoma is a benign bone tumor of osteoblastic origin.
  • Both tumors were resected with wide surgical margins and neither patient had adjuvant radiation or chemotherapy.
  • Differential diagnosis and immunohistochemical features potentially useful for refining diagnosis of osteoblastoma are also discussed.
  • [MeSH-major] Biomarkers, Tumor / analysis. Jaw Neoplasms / pathology. Osteoblastoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17091775.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


2. Dobashi Y, Suzuki S, Sato E, Hamada Y, Yanagawa T, Ooi A: EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors. Mod Pathol; 2009 Oct;22(10):1328-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors.
  • To gain the insight into the involvement of signaling mediated by the mammalian target of rapamycin (mTOR) in the phenotype and biological profiles of tumors and tumor-like lesions of the bone and soft tissue, we analyzed the expression and phosphorylation (activation) of mTOR and its correlation with the status of upstream and downstream modulator proteins Akt, p70S6-kinase (S6K), and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1), which we refer to collectively as mTOR cassette proteins.
  • Immunohistochemical analysis of 140 cases showed activation of Akt in 55% (61% in malignant and 27% in benign), and mTOR expression in 61% (66% in malignant and 39% in benign).
  • The preponderance of mTOR activation was found in tumors of peripheral nerve sheath (malignant peripheral nerve sheath tumor and schwannoma), skeletal muscle origin (rhabdomyosarcoma), and in those exhibiting epithelial nature (chordoma and synovial sarcoma).
  • Together with the result of immunoblotting analysis, it was shown that many of those particular tumors with mTOR activation exhibited activation of Akt, S6K, and 4E-BP1, suggesting the constitutive activation of the Akt/mTOR pathway.
  • We conclude that mTOR-mediated signaling proteins function not only in the proliferation of the tumor cells, but also in the differentiation and/or maintenance of morphological phenotypes in tumors of rhabdomyoblastic and nerve sheath cell origin.
  • Furthermore, mTOR signaling may also modulate morphogenesis of tumors exhibiting epithelial nature.
  • Overall, these results suggest that inhibitors of mTOR cassette may be useful as novel components of combined chemotherapy for a defined subset of bone and soft tissue sarcomas.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / analysis. Bone Neoplasms / enzymology. Phosphoproteins / analysis. Protein Kinases / analysis. Proto-Oncogene Proteins c-akt / analysis. Receptor, Epidermal Growth Factor / analysis. Ribosomal Protein S6 Kinases, 70-kDa / analysis. Signal Transduction. Soft Tissue Neoplasms / enzymology
  • [MeSH-minor] Cell Proliferation. Enzyme Activation. Humans. Immunoblotting. Immunohistochemistry. Mutation. Neoplasm Staging. Phosphorylation. Prognosis. TOR Serine-Threonine Kinases

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19648884.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / EIF4EBP1 protein, human; 0 / Phosphoproteins; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa
  •  go-up   go-down


3. Basu S, Baghel NS, Puri A, Shet T, Merchant NH: 18 F-FDG avid lesion due to coexistent fibrous dysplasia in a child of embryonal rhabdomyosarcoma: source of false positive FDG-PET. J Cancer Res Ther; 2010 Jan-Mar;6(1):92-4
Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With increasing use of 18 F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) in the current oncological practice, there is a growing body of evidence of false positive scans due to various benign conditions.
  • The patient was a case of ERMS (presenting with left cervical mass with intrathoracic extension) who was treated successfully with chemotherapy and was referred for FDG-PET to evaluate the disease status.
  • The scan was extended up to foot in view of the fact that a prior bone scan had shown a focal uptake in the similar location.
  • The computed tomography (CT) scan of the same region showed cortical thickening and increased density within the medullary cavity in the shaft of the tibia.
  • A histopathological diagnosis was sought for and the lesion was subsequently proven to be fibrous dysplasia by histopathology of the bone piece obtained from the right tibial lesion by J needle biopsy.
  • The present case is a useful addition to the current body of literature of false positive 18 F-FDG-PET study due to a benign skeletal pathology and underscores the importance of high index of suspicion and careful clinicoradiopathologic correlation, whenever one comes across such an unusual PET finding.
  • [MeSH-major] Fibrous Dysplasia of Bone / radionuclide imaging. Fluorodeoxyglucose F18. Radiopharmaceuticals. Rhabdomyosarcoma, Embryonal / radionuclide imaging. Soft Tissue Neoplasms / radionuclide imaging
  • [MeSH-minor] Child. False Positive Reactions. Humans. Male. Neoplasm Metastasis / pathology. Positron-Emission Tomography. Tibia / pathology

  • Genetic Alliance. consumer health - Fibrous Dysplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479556.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


Advertisement
4. von Chamier G, Holl-Wieden A, Stenzel M, Raab P, Darge K, Girschick HJ, Beer M: Pitfalls in diagnostics of hip pain: osteoid osteoma and osteoblastoma. Rheumatol Int; 2010 Jan;30(3):395-400
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteoid osteoma and osteoblastoma are benign bone tumors that occur most often in adolescents and predominantly in males.
  • Typical clinical symptoms, such as reduced range of motion of adjacent joints, nocturnal bone pain and relief of pain using non-steroidal anti-inflammatory drug therapy especially in osteoid osteoma may lead to the correct diagnosis.
  • In radiographic examinations, the initial changes are often uncharacteristic causing further delay in diagnosis.
  • Magnetic resonance imaging is increasingly used for screening, but early findings in the course of disease might not lead to the definite diagnosis.
  • To demonstrate pitfalls in the diagnostic pathway of hip pain caused by benign bone tumors, we present two cases with osteoid osteoma and one with osteoblastoma.
  • [MeSH-major] Arthralgia / etiology. Bone Neoplasms / pathology. Diagnostic Errors / prevention & control. Hip Joint / pathology. Osteoblastoma / pathology. Osteoma, Osteoid / pathology
  • [MeSH-minor] Adolescent. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Arthrography. Child. Diagnosis, Differential. Female. Femur Neck / diagnostic imaging. Femur Neck / pathology. Humans. Magnetic Resonance Imaging / methods. Male. Predictive Value of Tests. Sensitivity and Specificity. Synovial Membrane / diagnostic imaging. Synovial Membrane / pathology. Ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Rheum Dis. 2005 Feb;64(2):279-85 [15647436.001]
  • [Cites] N Engl J Med. 2007 Nov 29;357(22):2277-84 [18046031.001]
  • [Cites] Acta Radiol. 2001 Jan;42(1):6-9 [11167323.001]
  • [Cites] Top Magn Reson Imaging. 2002 Aug;13(4):219-29 [12409690.001]
  • [Cites] Clin Orthop Relat Res. 2005 Apr;(433):171-7 [15805954.001]
  • [Cites] Clin Imaging. 2000 Jan-Feb;24(1):19-27 [11120413.001]
  • [Cites] Radiology. 1990 Jun;175(3):783-90 [2343130.001]
  • [Cites] Radiology. 1993 Jan;186(1):227-32 [8416569.001]
  • [Cites] Arch Orthop Trauma Surg. 2006 Dec;126(10):660-7 [16927097.001]
  • [Cites] Radiology. 2003 Jun;227(3):691-700 [12773675.001]
  • [Cites] Radiology. 2003 Oct;229(1):171-5 [12944597.001]
  • [Cites] Radiographics. 1992 Nov;12(6):1119-34; discussion 1135-6 [1439015.001]
  • [Cites] J Bone Joint Surg Br. 1999 Sep;81(5):814-20 [10530842.001]
  • [Cites] Clin Radiol. 2003 Nov;58(11):845-52 [14581007.001]
  • [Cites] Am J Surg Pathol. 1991 Apr;15(4):381-7 [2006718.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2005 Nov;13(4):757-74 [16275582.001]
  • [Cites] Skeletal Radiol. 1993 Oct;22(7):485-500 [8272884.001]
  • [Cites] Radiology. 1994 Apr;191(1):217-23 [8134575.001]
  • [Cites] Skeletal Radiol. 2002 Oct;31(10):559-69 [12324824.001]
  • [Cites] J Child Neurol. 2007 Feb;22(2):170-5 [17621478.001]
  • (PMID = 19444452.001).
  • [ISSN] 1437-160X
  • [Journal-full-title] Rheumatology international
  • [ISO-abbreviation] Rheumatol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal
  •  go-up   go-down


5. O'Donnell TM, Devitt AT, Kutty S, Fogarty EE: Recurrent congenital haemangiopericytoma in a child. J Bone Joint Surg Br; 2001 Mar;83(2):269-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A five-day-old boy was referred with a soft-tissue mass in his right upper arm.
  • Open biopsy confirmed the diagnosis of congenital haemangiopericytoma.
  • After MRI and selective angiography, excision biopsy was carried out, but no adjuvant therapy was administered.
  • At further examination, four years and ten months later, he was noted to have three small nodules at the site of the original tumour.
  • Congenital haemangiopericytoma is a rare cause of a soft-tissue mass in children.
  • Most tumours are benign, and recurrence is uncommon.
  • The treatment is controversial, but most centres recommend the use of adjuvant chemotherapy, combined with complete excision.
  • We recommend treatment with doxorubicin.
  • Orthopaedic surgeons should be familiar with this tumour since 30% to 50% of cases occur in the limbs.
  • [MeSH-major] Hemangiopericytoma / congenital. Soft Tissue Neoplasms / congenital
  • [MeSH-minor] Arm. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Infant, Newborn. Male. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11284579.001).
  • [ISSN] 0301-620X
  • [Journal-full-title] The Journal of bone and joint surgery. British volume
  • [ISO-abbreviation] J Bone Joint Surg Br
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Uysal-Onganer P, Kawano Y, Caro M, Walker MM, Diez S, Darrington RS, Waxman J, Kypta RM: Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells. Mol Cancer; 2010 Mar 10;9:55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the prevalence of increased expression of Wnt-11 in patient tumours and the functions of Wnt-11 in prostate cancer cells were not known.
  • RESULTS: Wnt-11 protein levels in prostate tumours were determined by immunohistochemical analysis of prostate tumour tissue arrays.
  • Wnt-11 protein was elevated in 77/117 of tumours when compared with 27 benign prostatic hypertrophy specimens and was present in 4/4 bone metastases.
  • Androgen-depleted LNCaP prostate cancer cells form neurites and express genes associated with neuroendocrine-like differentiation (NED), a feature of prostate tumours that have a poor prognosis.
  • In contrast, Wnt-11 did not induce NSE expression in RWPE-1 cells, which are derived from benign prostate, suggesting that the role of Wnt-11 in NED is specific to prostate cancer.
  • CONCLUSIONS: These observations suggest that the increased level of Wnt-11 found in prostate cancer contributes to tumour progression by promoting NED, tumour cell survival and cell migration/invasion, and may provide an opportunity for novel therapy in prostate cancer.


7. Sangiorgi L, Gobbi GA, Lucarelli E, Sartorio SM, Mordenti M, Ghedini I, Maini V, Scrimieri F, Reggiani M, Bertoja AZ, Benassi MS, Picci P: Presence of telomerase activity in different musculoskeletal tumor histotypes and correlation with aggressiveness. Int J Cancer; 2001 May 20;95(3):156-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of telomerase activity in different musculoskeletal tumor histotypes and correlation with aggressiveness.
  • To investigate whether telomerase activity is an index of aggressiveness in bone and soft tissue lesions of the extremities, 66 biopsy samples from our tissue bank were studied.
  • These samples included 43 high-grade sarcomas, 9 aggressive benign tumors and 14 totally benign lesions.
  • All tumors investigated were positive for telomerase activity.
  • Among benign lesions, only 2 aneurysmal bone cysts showed higher telomerase activity than the cut-off point, whereas all the other benign lesions had lower activity.
  • Our results indicate that high levels of telomerase activity in bone and soft tissue lesions correlate with more aggressive clinical behavior in patients treated with surgery alone.
  • An interesting inverse correlation between telomerase activity and occurrence of pulmonary metastasis was detected in osteosarcoma patients treated with chemotherapy.
  • A parallel increase of telomerase activity and malignancy was observed in the adipose and cartilagineous tissue lesions.
  • Our data suggest that telomerase activity could be considered a marker of tumor aggressiveness for bone and soft tissue lesions.
  • The results obtained in osteosarcoma samples suggest that low levels of telomerase activity may be predictive of the prognosis and should influence the therapeutic protocol.
  • [MeSH-major] Bone Neoplasms / enzymology. Soft Tissue Neoplasms / enzymology. Telomerase / metabolism
  • [MeSH-minor] Humans. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11307148.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


8. Moriceau G, Ory B, Gobin B, Verrecchia F, Gouin F, Blanchard F, Redini F, Heymann D: Therapeutic approach of primary bone tumours by bisphosphonates. Curr Pharm Des; 2010;16(27):2981-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic approach of primary bone tumours by bisphosphonates.
  • Bone tumours can be dissociated in two main categories: i) primary bone tumours (benign or malignant) including mainly osteosarcoma and other sarcomas.ii)and giant cell tumour and bone metastases originate from others cancer (Breast, prostate, kidney cancer, etc).
  • These tumours are able to destroy or/and induce a new calcified matrix.
  • However, the first step of bone tumour development is associated with an induction of bone resorption and the establishment of a vicious cycle between the osteoclasts and the tumour growth.
  • Indeed, bone resorption contributes to the pathogenesis of bone tumour by the release of cytokines (IL6, TNFα) which govern the bone tumour's development and which are trapped into the bone matrix.
  • Bisphosphonates (BPs) are chemical compounds of P-C-P structure with a high affinity for bone hydroxyapatite crystals.
  • Thus, they have been used as a carrier for radio nucleotides to develop novel approaches of bone imaging.
  • BPs exert also indirect anti-tumour activities in vivo.
  • Indeed, BPs directly interfere with the bone microenvironment and target osteoclasts, endothelial cells and immune cells (tumour-associated macrophages, γ9δ2 T cells).
  • BPs induce tumour cell death in vitro and same activity is suspected in vivo.
  • The present review summarizes the mechanisms of actions of BPs as well as their clinical interests in bone primary tumours.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Diphosphonates / pharmacology. Diphosphonates / therapeutic use. Drug Design
  • [MeSH-minor] Animals. Bone Density Conservation Agents / pharmacology. Bone Density Conservation Agents / therapeutic use. Chondrosarcoma / drug therapy. Giant Cell Tumor of Bone / drug therapy. Humans. Osteosarcoma / drug therapy

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20722622.001).
  • [ISSN] 1873-4286
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bone Density Conservation Agents; 0 / Diphosphonates
  •  go-up   go-down


9. Mintz S, Velez I: Osteoid osteoma of the zygoma: report of an unusual case. J Am Dent Assoc; 2007 Jun;138(6):793-7
Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Osteoid osteoma is a benign tumor of bone characterized by pain, usually occurring at night, that shows a dramatic response to aspirin.
  • On the basis of the images and the biopsy report, the authors made a diagnosis of osteoid osteoma.
  • In this article, they describe the treatment of and new modalities of therapy for this condition.
  • [MeSH-minor] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Aspirin / therapeutic use. Facial Pain / drug therapy. Facial Pain / etiology. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17545268.001).
  • [ISSN] 0002-8177
  • [Journal-full-title] Journal of the American Dental Association (1939)
  • [ISO-abbreviation] J Am Dent Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; R16CO5Y76E / Aspirin
  •  go-up   go-down


10. Ruggieri P, Angelini A, Montalti M, Pala E, Calabrò T, Ussia G, Abati CN, Mercuri M: Tumours and tumour-like lesions of the hip in the paediatric age: a review of the Rizzoli experience. Hip Int; 2009 Jan-Mar;19 Suppl 6:S35-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumours and tumour-like lesions of the hip in the paediatric age: a review of the Rizzoli experience.
  • Bone tumours and tumour-like lesions of the hip in children are rare.
  • Signs and symptoms of these tumours are generally nonspecific.
  • Delay of diagnosis is not uncommon.
  • A high index of suspicion in young patients presenting with persistent pain and without history of trauma, that is unresolved with conservative therapy should prompt further investigation, including radiographs or computed tomography scan of the pelvis.
  • In the experience of the Istituto Rizzoli, in patients less than 14 years (mean 9 years, ranged from 6 months to 14 years), 752 tumours and tumours-like lesions occurred in the pelvis or proximal femur, involving the hip.
  • Tumour-like lesions accounted for 322 cases (simple bone cyst in 255, eosinophilic granuloma in 43, aneurismal bone cyst in 34), benign tumours for 340 cases (osteoid osteoma in 229, fibrous dysplasia in 63, exostosis in 48) and malignant tumours for 80 cases (Ewing's sarcoma in 53 and osteosarcoma in 27).
  • The epidemiology, pathology, clinical presentation, and radiograph findings are discussed for each of these tumours.Treatment of these tumours differs from observation or minimally invasive treatment for most pseudotumoural lesions, intralesional excision or termoablation for benign bone tumours and wide resection for malignant bone tumours.
  • In this latter group, chemotherapy is required and often administered pre- and postoperatively.
  • [MeSH-minor] Adolescent. Bone Cysts, Aneurysmal / epidemiology. Bone Cysts, Aneurysmal / pathology. Bone Cysts, Aneurysmal / therapy. Child. Child, Preschool. Databases, Factual. Eosinophilic Granuloma / epidemiology. Eosinophilic Granuloma / pathology. Eosinophilic Granuloma / therapy. Exostoses / epidemiology. Exostoses / pathology. Exostoses / therapy. Female. Fibrous Dysplasia, Monostotic / epidemiology. Fibrous Dysplasia, Monostotic / pathology. Fibrous Dysplasia, Monostotic / therapy. Humans. Infant. Italy / epidemiology. Male. Pain

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19306246.001).
  • [ISSN] 1724-6067
  • [Journal-full-title] Hip international : the journal of clinical and experimental research on hip pathology and therapy
  • [ISO-abbreviation] Hip Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Gasbarrini A, Cappuccio M, Donthineni R, Bandiera S, Boriani S: Management of benign tumors of the mobile spine. Orthop Clin North Am; 2009 Jan;40(1):9-19, v

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of benign tumors of the mobile spine.
  • In the treatment of primary tumors, complete local eradication is the main goal, as an oncologically appropriate surgical treatment can substantially improve the prognosis and even be considered a life-saving procedure.
  • In deciding the best treatment for primary bone tumors of the spine, the choice of surgery, radiation therapy, chemotherapy, selective arterial embolization, or other medical treatments alone or in combination is based on diagnosis, staging, and a deep understanding of the biology and the behavior of each tumor.
  • This article is a guide to diagnosing and treating such rare tumors.
  • [MeSH-major] Spinal Neoplasms / diagnosis. Spinal Neoplasms / surgery
  • [MeSH-minor] Humans. Neoplasm Staging. Spinal Diseases / diagnosis. Spinal Diseases / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19064052.001).
  • [ISSN] 0030-5898
  • [Journal-full-title] The Orthopedic clinics of North America
  • [ISO-abbreviation] Orthop. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 44
  •  go-up   go-down


12. Stegger L, Juergens KU, Kliesch S, Wormanns D, Weckesser M: Unexpected finding of elevated glucose uptake in fibrous dysplasia mimicking malignancy: contradicting metabolism and morphology in combined PET/CT. Eur Radiol; 2007 Jul;17(7):1784-6
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fibrous dysplasia is a common benign disorder of bone in which fibro-osseous tissue replaces bone spongiosa.
  • Lesions have a typical appearance on computed tomography (CT) images and regularly show a markedly increased uptake in bone scintigraphy using (99m)Tc-labelled methylene diphosphonate ((99m)Tc-MDP) as radiotracer.
  • The glucose avidity of these lesions depicted by positron emission tomography (PET) using the radiolabelled glucose derivative (18)F-fluoro-2-deoxy-glucose (FDG) is less well known since FDG-PET does not have a role in the assessment of this disease.
  • [MeSH-major] Blood Glucose / metabolism. Fibrous Dysplasia, Polyostotic / diagnosis. Image Processing, Computer-Assisted. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Carcinoma, Embryonal / diagnosis. Carcinoma, Embryonal / drug therapy. Carcinoma, Embryonal / secondary. Carcinoma, Embryonal / surgery. Combined Modality Therapy. Diagnosis, Differential. Femoral Neoplasms / diagnosis. Femoral Neoplasms / secondary. Fluorodeoxyglucose F18. Humans. Male. Neoplasm Recurrence, Local / diagnosis. Postoperative Complications / diagnosis. Sensitivity and Specificity. Testicular Neoplasms / diagnosis. Testicular Neoplasms / drug therapy. Testicular Neoplasms / surgery

  • Genetic Alliance. consumer health - Fibrous Dysplasia.
  • MedlinePlus Health Information. consumer health - Blood Sugar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Nucl Med. 2004 Mar;29(3):177-80 [15162988.001]
  • [Cites] Nuklearmedizin. 1995 Dec;34(6):229-31 [8596739.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):173-80 [9440740.001]
  • [Cites] Clin Nucl Med. 1986 Jun;11(6):426-9 [3720157.001]
  • [Cites] Eur Radiol. 2005 Dec;15(12 ):2483-6 [15711835.001]
  • [Cites] Clin Nucl Med. 1989 Dec;14 (12 ):928-9 [2605856.001]
  • [Cites] Radiographics. 1990 May;10 (3):519-37 [2188311.001]
  • [Cites] AJR Am J Roentgenol. 1982 Nov;139(5):943-8 [6981980.001]
  • [Cites] Clin Nucl Med. 2005 Aug;30(8):571-3 [16024960.001]
  • [Cites] Eur Radiol. 2006 May;16(5):1054-65 [16365730.001]
  • [Cites] Clin Nucl Med. 1987 Aug;12 (8):627-31 [3665301.001]
  • [Cites] Ann Nucl Med. 1998 Jun;12 (3):153-5 [9673717.001]
  • [Cites] AJR Am J Roentgenol. 2002 Mar;178(3):717-20 [11856704.001]
  • (PMID = 17066288.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Blood Glucose; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


13. Burnett RC, Vernau W, Modiano JF, Olver CS, Moore PF, Avery AC: Diagnosis of canine lymphoid neoplasia using clonal rearrangements of antigen receptor genes. Vet Pathol; 2003 Jan;40(1):32-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of canine lymphoid neoplasia using clonal rearrangements of antigen receptor genes.
  • Although the diagnosis of canine leukemia and lymphoma in advanced stages is usually uncomplicated, some presentations of the disease can be a diagnostic challenge.
  • In certain situations, lymphoma and leukemia can be difficult to distinguish from a benign reactive proliferation of lymphocytes.
  • Because clonality is the hallmark of malignancy, we have developed an assay that uses the polymerase chain reaction to amplify the variable regions of immunoglobulin genes and T-cell receptor genes to detect the presence of a clonal lymphocyte population.
  • Dilution analysis showed that the clonal rearrangement could be detected when 0.1-10% of the DNA was derived from neoplastic cells, depending on the source tissue.
  • Potential applications of this assay include the diagnosis of lymphoma or leukemia in biopsy samples, cavity fluids, fine needle aspirates, bone marrow and peripheral blood; the determination of lineage (B or T cell); staging of lymphoma; and detection of residual disease after chemotherapy.
  • [MeSH-minor] Animals. Clone Cells. DNA, Neoplasm / chemistry. DNA, Neoplasm / genetics. Dogs. Genes, Immunoglobulin / genetics. Immunophenotyping. Polymerase Chain Reaction / methods. Polymerase Chain Reaction / veterinary. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12627711.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


14. Trieb K, Gerth R, Windhager R, Grohs JG, Holzer G, Berger P, Kotz R: Serum antibodies against the heat shock protein 60 are elevated in patients with osteosarcoma. Immunobiology; 2000 Jan;201(3-4):368-76
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteosarcoma is the most frequent malignant bone tumor, mainly occurring in the second and third decade of life.
  • Diagnosis is limited to clinical symptoms, radiology and histology, but so far no diagnostic laboratory tests are available.
  • Heat shock proteins (hsp), highly conserved proteins performing vital intracellular chaperoning functions and preventing cells from death, have been shown to be involved in tumor immunity.
  • We analyzed 75 sera from 23 patients with high-grade osteosarcoma, 8 patients with chondrosarcoma, 10 patients with Ewing's sarcoma, 5 patients with soft tissue sarcoma, 11 patients with benign bone tumors at the time of diagnosis and from 18 healthy controls with an indirect one-site enzyme linked immunosorbent assay (ELISA) for the presence of anti-hsp60 and 70 antibodies.
  • Only one of the 18 healthy controls (1/18, 5.6%; titer 0.22 U/ml), two of the Ewing's sarcoma patients (2/10, 20%; titer 0.2 +/- 0.09 U/ml), two of the patients with a benign bone tumor (2/11, 18%; titer 0.22 +/- 0.16 U/ml) and one of the chondrosarcoma patients (1/8, 12.5%; titer 0.14 U/ml) were positive, whereas all others, including all soft tissue sarcomas were negative throughout.
  • The level of the anti-hsp60 antibodies did not correlate with clinical parameters such as response to preoperative chemotherapy, duration of symptoms, age, gender, tumor size, serum alkaline-phosphatase levels and metastases.
  • Although no difference in anti-hsp70 antibodies could be observed between sera from patients and healthy controls, a positive correlation was found for the presence of anti-hsp70 serum antibodies and lung metastases at the time of diagnosis in osteosarcoma patients.
  • These data suggest an increase of anti-hsp60 antibodies at the time of first diagnosis of osteosarcoma.
  • These findings should therefore give rise to further investigations on a group of new markers for the diagnosis of osteosarcoma.
  • [MeSH-major] Antibodies, Neoplasm / blood. Bone Neoplasms / immunology. Chaperonin 60 / immunology. Osteosarcoma / immunology


15. Mehta PB, Jenkins BL, McCarthy L, Thilak L, Robson CN, Neal DE, Leung HY: MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene; 2003 Mar 6;22(9):1381-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined MEK5 expression in 127 cases of prostate cancer and 20 cases of benign prostatic hypertrophy (BPH) by immunohistochemistry and compared the results to clinical parameters.
  • We demonstrated that MEK5 expression is increased in prostate cancer as compared to benign prostatic tissue.
  • As the MEK5/ERK5 interaction is highly specific, it represents a potential target of therapy.
  • [MeSH-major] Adenocarcinoma / enzymology. Bone Neoplasms / secondary. Mitogen-Activated Protein Kinase Kinases / physiology. Neoplasm Invasiveness / genetics. Neoplasm Proteins / physiology. Prostatic Neoplasms / enzymology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Division. Cell Line. Cell Movement. Collagen. Drug Combinations. Enzyme Induction. Gene Expression Regulation, Neoplastic. Humans. Kidney. Laminin. MAP Kinase Kinase 5. Male. Matrix Metalloproteinase 2 / biosynthesis. Matrix Metalloproteinase 2 / genetics. Matrix Metalloproteinase 9 / biosynthesis. Matrix Metalloproteinase 9 / genetics. Middle Aged. Prostatic Hyperplasia / enzymology. Proteoglycans. Recombinant Fusion Proteins / biosynthesis. Recombinant Fusion Proteins / genetics. Signal Transduction. Survival Analysis. Transcription Factor AP-1 / metabolism. Transfection. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12618764.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Laminin; 0 / Neoplasm Proteins; 0 / Proteoglycans; 0 / Recombinant Fusion Proteins; 0 / Transcription Factor AP-1; 119978-18-6 / matrigel; 9007-34-5 / Collagen; EC 2.7.1.- / MAP2K5 protein, human; EC 2.7.12.2 / MAP Kinase Kinase 5; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


16. Koswig S, Budach V: [The role of radiotherapy in the treatment of bone neoplasms]. Chirurg; 2002 Dec;73(12):1174-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of radiotherapy in the treatment of bone neoplasms].
  • Primary malignant bone neoplasms are relatively rare.
  • The most common bone tumors are osteosarcoma,Ewing's sarcoma,chondrosarcoma, fibrosarcoma,malignant fibrous histiocytoma of bone, giant cell tumor, aneurysmal bone cyst and chordoma.
  • These tumors are generally considered to be a radioresistant entities, but it has been suggested that radiotherapy may be effective in a palliative and in some curative situations, if a sufficient dose is given to an adequate volume.
  • Only for the management of primary Ewing's sarcoma the radiation therapy is an essential part in the multimodal therapy concept.
  • The most common bone neoplasms and the role of the radiotherapy are discussed in these chapter.
  • [MeSH-major] Bone Neoplasms / radiotherapy. Chondrosarcoma / radiotherapy. Osteosarcoma / radiotherapy. Sarcoma, Ewing / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Cysts, Aneurysmal / radiotherapy. Bone Cysts, Aneurysmal / surgery. Child. Child, Preschool. Chordoma / radiotherapy. Chordoma / surgery. Clinical Trials as Topic. Combined Modality Therapy. Dose Fractionation. Female. Fibrosarcoma / radiotherapy. Fibrosarcoma / surgery. Follow-Up Studies. Giant Cell Tumors / radiotherapy. Giant Cell Tumors / surgery. Histiocytoma, Benign Fibrous / drug therapy. Histiocytoma, Benign Fibrous / radiotherapy. Histiocytoma, Benign Fibrous / surgery. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Palliative Care. Postoperative Care. Radiotherapy Dosage. Risk Factors. Time Factors

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12491046.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 33
  •  go-up   go-down


17. Kim MS, Lee SY, Cho WH, Song WS, Koh JS, Lee JA, Yoo JY, Shin DS, Jeon DG: Prognostic effects of doctor-associated diagnostic delays in osteosarcoma. Arch Orthop Trauma Surg; 2009 Oct;129(10):1421-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: The authors identified 26 osteosarcoma patients who had undergone inappropriate procedure-associated diagnostic delays of more than 45 days after surgery, calculated overall survival rates, and analyzed clinicopathologic characteristics.
  • RESULTS: Initial clinical impressions were of a benign bone tumor in 15 patients, fracture in 8, and infection in 3.
  • After initial inappropriate procedures, primary surgeons failed to send a tissue sample to a pathologist for definite diagnosis in 12 cases, and pathologists made incorrect diagnoses in the other 14.
  • Following referral to our institute, 22 underwent both surgery and chemotherapy and the remaining 4 patients underwent chemotherapy only.
  • CONCLUSIONS: The present study shows that doctor-associated diagnostic delay superimposed on an inappropriate primary procedure has a significant detrimental effect on overall survival in osteosarcoma.
  • [MeSH-major] Bone Neoplasms / diagnosis. Osteosarcoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19280203.001).
  • [ISSN] 1434-3916
  • [Journal-full-title] Archives of orthopaedic and trauma surgery
  • [ISO-abbreviation] Arch Orthop Trauma Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Moser A, Hoffmann KM, Walch C, Sovinz P, Lackner H, Schwinger W, Benesch M, Fritz G, Urban C: Intracranial reparative giant cell granuloma secondary to cholesteatoma in a 15-year-old girl. J Pediatr Hematol Oncol; 2008 Dec;30(12):935-7
Hazardous Substances Data Bank. DICLOFENAC .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imaging studies revealed an intracranial mass of the right temporal bone causing temporal lobe displacement.
  • A first biopsy led to the diagnosis of intracranial giant cell reparative granuloma (GCRG), a rare benign tumor of the bone or soft tissue that can show expansive growth.
  • Facial nerve palsy responded to treatment with diclofenac and physiotherapy, however, the intracranial lesion progressed at follow-up.
  • Cholesteatoma should be considered as a trigger for intracranial GCRG growth, especially if adjacent to the temporal bone.
  • [MeSH-major] Bone Diseases / etiology. Cholesteatoma, Middle Ear / complications. Granuloma, Giant Cell / etiology. Temporal Bone
  • [MeSH-minor] Adolescent. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Diclofenac / therapeutic use. Facial Paralysis / drug therapy. Facial Paralysis / etiology. Female. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Cholesteatoma.
  • MedlinePlus Health Information. consumer health - Bone Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131785.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 144O8QL0L1 / Diclofenac
  •  go-up   go-down


19. Donthineni R, Boriani L, Ofluoglu O, Bandiera S: Metastatic behaviour of giant cell tumour of the spine. Int Orthop; 2009 Apr;33(2):497-501
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic behaviour of giant cell tumour of the spine.
  • Lung metastases from giant cell tumours (GCT) of the spine have not been specifically addressed in the literature.
  • We reviewed our cases and compared the incidence, treatment, and outcomes with those from the extremities.
  • Four of the seven patients had presented to our institution with a spine recurrence after previous treatments and the rest developed recurrences later.
  • The treatments for the lung nodules consisted of metastectomy in two and chemotherapy in six patients.
  • Our series shows a higher metastatic rate from spine GCT as compared to those from the extremities, but the overall behaviour and treatment outcomes of the lung metastases are similar.
  • When there is a recurrence of GCT, with or without metastases, the local and possibly the metastases should be biopsied to confirm the original diagnosis.
  • Progression of benign GCT into an aggressive sarcoma has been documented, and the method of management should be altered.
  • [MeSH-major] Bone Neoplasms / pathology. Giant Cell Tumor of Bone / secondary. Lung Neoplasms / secondary. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adolescent. Adult. Biopsy, Needle. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Assessment. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 2002 Aug;(401):202-8 [12151897.001]
  • [Cites] Int Orthop. 2006 Dec;30(6):499-504 [16909252.001]
  • [Cites] J Bone Joint Surg Am. 1975 Mar;57(2):167-73 [1112843.001]
  • [Cites] Cancer. 1980 Oct 1;46(7):1641-9 [7417958.001]
  • [Cites] J Bone Joint Surg Am. 1984 Feb;66(2):269-74 [6693454.001]
  • [Cites] Clin Orthop Relat Res. 1988 Dec;(237):275-85 [3056645.001]
  • [Cites] Chir Organi Mov. 1990;75(1 Suppl):204-5 [2249533.001]
  • [Cites] AJR Am J Roentgenol. 1992 Feb;158(2):331-4 [1729794.001]
  • [Cites] J Bone Joint Surg Br. 1993 Jan;75(1):148-54 [8421014.001]
  • [Cites] Clin Orthop Relat Res. 1994 May;(302):219-30 [8168305.001]
  • [Cites] Int Orthop. 1996;20(3):172-6 [8832321.001]
  • [Cites] Clin Orthop Relat Res. 1997 Feb;(335):253-61 [9020226.001]
  • [Cites] Clin Orthop Relat Res. 1997 May;(338):205-14 [9170381.001]
  • [Cites] J Bone Joint Surg Br. 1998 Jan;80(1):43-7 [9460951.001]
  • [Cites] J Thorac Cardiovasc Surg. 1998 Oct;116(4):649-51 [9766596.001]
  • [Cites] Cancer. 1964 Apr;17:461-72 [14136529.001]
  • [Cites] Clin Orthop Relat Res. 2005 Sep;438:116-22 [16131879.001]
  • [Cites] J Bone Joint Surg Am. 1970 Jun;52(4):619-64 [5479455.001]
  • (PMID = 18461324.001).
  • [ISSN] 1432-5195
  • [Journal-full-title] International orthopaedics
  • [ISO-abbreviation] Int Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2899057
  •  go-up   go-down


20. Takahashi S, Okada K, Nagasawa H, Shimada Y, Sakamoto H, Itoi E: Osteosarcoma occurring in osteogenesis imperfecta. Virchows Arch; 2004 May;444(5):454-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a case history of a 24-year-old male with osteogenesis imperfecta (OI) who developed osteosarcoma of the left thigh.
  • High-dose ifosfamide therapy caused marked tumor regression of multiple lung metastases.
  • Immunohistochemically, the tumor cells were diffusely positive for the p53 protein.
  • The radiographic characteristics, including irregularly distributed osteolytic lesions and cortical discontinuity, should not be confused with hyperplastic callus formation, a benign process.
  • A biopsy is critical to establish the differential diagnosis between osteosarcoma and common hyperplastic callus formation in OI; however, it must be applied with great care.
  • [MeSH-major] Bone Neoplasms / complications. Osteogenesis Imperfecta / complications. Osteosarcoma / complications
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. DNA Mutational Analysis. DNA, Neoplasm / analysis. Doxorubicin / administration & dosage. Humans. Ifosfamide / therapeutic use. Immunohistochemistry. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Methotrexate / administration & dosage. Radiography, Thoracic. Thigh / pathology. Thigh / surgery. Tomography, X-Ray Computed. Treatment Outcome. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Osteogenesis imperfecta.
  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Osteogenesis Imperfecta.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Br. 1967 May;49(2):314-23 [5229569.001]
  • [Cites] Cancer Res. 1994 Sep 15;54(18):4855-78 [8069852.001]
  • [Cites] Cancer Res. 1993 Feb 1;53(3):468-71 [8425179.001]
  • [Cites] Clin Orthop Relat Res. 1975 Sep;(111):14-22 [50894.001]
  • [Cites] Skeletal Radiol. 1995 May;24(4):308-10 [7544031.001]
  • [Cites] Pathology. 1999 Feb;31(1):52-4 [10212924.001]
  • [Cites] J Bone Joint Surg Am. 1979 Jun;61(4):606-8 [285932.001]
  • [Cites] J Pathol. 1994 Jan;172(1):1-4 [7931821.001]
  • [Cites] Int Orthop. 2002;26(2):126-8 [12078875.001]
  • [Cites] Cancer Res. 1992 Nov 15;52(22):6194-9 [1423262.001]
  • [Cites] Mod Pathol. 1996 Jan;9(1):1-6 [8821948.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):467-72 [8636759.001]
  • [Cites] J Cell Biochem. 1996 Oct;63(1):37-50 [8891902.001]
  • [Cites] Cancer Res. 1990 Dec 15;50(24):7950-4 [2253237.001]
  • [Cites] Eur J Pediatr. 1978 Oct 12;129(3):215-8 [279454.001]
  • [Cites] J Cancer Res Clin Oncol. 1996;122(9):559-65 [8781571.001]
  • [Cites] Pediatr Radiol. 1979 Apr 19;8(2):110-2 [286967.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Feb;86(2):136-42 [8603340.001]
  • (PMID = 15214333.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p53; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 21
  •  go-up   go-down


21. Yel L, Liao O, Lin F, Gupta S: Severe T- and B-cell immune deficiency associated with malignant thymoma. Ann Allergy Asthma Immunol; 2003 Nov;91(5):501-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Immunodeficiency with thymoma syndrome is a rare disorder that generally occurs after the fourth decade of life.
  • Typically, thymic tumors are benign, and gradually developing immunodeficiency consists of hypogammaglobulinemia with low B-cell counts and an inverted CD4+/CD8+ T-cell ratio due to excessive CD8+ T cells.
  • During chemotherapy and radiotherapy, he experienced recurrent episodes of pulmonary infections due to Haemophilus influenza and Serratia marcescens and persistent oral thrush.
  • RESULTS: Sixteen months after the diagnosis of thymoma, the immunological evaluation revealed profound lymphopenia, eosinopenia, very low counts of both CD4+ T cells and CD8+ T cells, and a normal CD4+/CD8+ ratio with negative delayed-type hypersensitivity skin test results.
  • Despite treatment with intravenous immunoglobulin, the patient died of respiratory insufficiency and sepsis secondary to a chronic pulmonary infection.
  • A normal CD4+/CD8+ ratio and the absence of peripheral B cells suggest a bone marrow defect that affects both T and B cells in the pathogenesis of this syndrome.
  • Comprehensive immunological evaluation should be performed when thymoma is diagnosed to initiate an early and effective treatment to prevent life-threatening complications.
  • [MeSH-minor] Adult. Antibody Formation / immunology. Antibody Specificity / immunology. CD4-CD8 Ratio. Humans. Immunoglobulin G / blood. Immunoglobulin G / immunology. Lymphocyte Count. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Serratia Infections / diagnosis. Serratia Infections / immunology. Serratia Infections / microbiology. Serratia marcescens / immunology. Severity of Illness Index. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14692437.001).
  • [ISSN] 1081-1206
  • [Journal-full-title] Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • [ISO-abbreviation] Ann. Allergy Asthma Immunol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin G
  •  go-up   go-down


22. Simmons C, Amir E, Dranitsaris G, Clemons M, Wong B, Veith R, Cole DE: Altered calcium metabolism in patients on long-term bisphosphonate therapy for metastatic breast cancer. Anticancer Res; 2009 Jul;29(7):2707-11
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered calcium metabolism in patients on long-term bisphosphonate therapy for metastatic breast cancer.
  • BACKGROUND: Bisphosphonates (BPs) are considered the standard of care in metastatic breast cancer (MBC) patients with bone metastases.
  • MATERIALS AND METHODS: An exploratory analysis of serum calcium, parathyroid (PTH), and 25 hydroxycholecalsiferol (25-(OH)D) levels and their inter-relationships was undertaken in 46 MBC patients who had been on prolonged BP therapy.
  • These results were compared to a historical control group of 420 patients without bone or mineral disease who were matched for gender, age, baseline renal function and season of seological testing.
  • CONCLUSION: In MBC patients with prolonged BP use, there appears to be a state of hyperparathyroidism similar to that seen with BP use in benign bone disease.
  • [MeSH-major] Breast Neoplasms / metabolism. Calcium / metabolism. Diphosphonates / therapeutic use. Neoplasm Metastasis / drug therapy


23. Kawano K, Ono K, Yada N, Takahashi Y, Kashima K, Yokoyama S, Yanagisawa S: Malignant calcifying epithelial odontogenic tumor of the mandible: report of a case with pulmonary metastasis showing remarkable response to platinum derivatives. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Jul;104(1):76-81
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant calcifying epithelial odontogenic tumor of the mandible: report of a case with pulmonary metastasis showing remarkable response to platinum derivatives.
  • We describe a case of CEOT of the mandible, which underwent malignant transformation and developed metastatic tumors of the lung after repeated local recurrence.
  • The primary tumor revealed typical histological features of benign CEOT showing sheets of polyhedral epithelial cells associated with abundant eosinophilic amyloid-like materials.
  • On the other hand, the locally recurrent tumors had malignant features, such as increased nuclear pleomorphism with frequent mitotic figures and vascular invasion of tumor cells, as well as increased proliferative activity assessed by immunostaining for Ki-67.
  • Chemotherapy was carried out against the pulmonary metastatic lesions, which showed a drastic response after 3 courses of intravenous administration of cisplatin (CDDP).
  • To date, a total of 6 courses of CDDP and 6 courses of nedaplatin (CDGP) have been done, and the remaining pulmonary tumors have been dormant.
  • This suggests that platinum derivatives could be a chemotherapeutic agent of choice against this rare tumor.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Lung Neoplasms / drug therapy. Mandibular Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Odontogenic Cyst, Calcifying / drug therapy
  • [MeSH-minor] Bone Transplantation. Humans. Male. Mandible / radiography. Mandible / surgery. Middle Aged. Organoplatinum Compounds / therapeutic use

  • Genetic Alliance. consumer health - Calcifying Epithelial Odontogenic Tumor.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577547.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


24. Daw NC, Mahmoud HH, Meyer WH, Jenkins JJ, Kaste SC, Poquette CA, Kun LE, Pratt CB, Rao BN: Bone sarcomas of the head and neck in children: the St Jude Children's Research Hospital experience. Cancer; 2000 May 1;88(9):2172-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone sarcomas of the head and neck in children: the St Jude Children's Research Hospital experience.
  • BACKGROUND: Bone sarcomas of the head and neck are difficult to resect.
  • The authors reviewed their institutional experience with these tumors to characterize patients' clinical findings and to assess the impact of surgical resection on outcome.
  • METHODS: The records of the 28 patients with bone sarcomas originating in the head and neck treated at St. Jude Children's Research Hospital between March 1962 and January 1998 were reviewed.
  • Primary tumor sites included the maxilla (13), skull (10), mandible (2), and other sites (3).
  • All but one patient with Ewing sarcoma had localized disease at the time of diagnosis.
  • All patients underwent surgery: complete resection, 8; gross total resection, 4; incomplete resection, 14; and biopsy only, 2; 22 also received chemotherapy.
  • Twelve patients survived a median of 8.4 years after diagnosis, 14 died of disease, and 2 died of unrelated causes.
  • Local disease progression was evident in 12 patients (9 with osteosarcoma, 2 with MFH, and 1 with Ewing sarcoma) who died of disease, 9 of whom had the initial treatment of biopsy alone or incomplete resection.
  • Patients with osteosarcoma who had the initial treatment of incomplete resection or biopsy alone were more likely to experience local failure (P = 0.001) and had poorer survival (P = 0.014) than those who underwent complete or gross total resection.
  • CONCLUSIONS: Bone sarcomas of the head and neck are rare among children and most often are localized at the time of diagnosis.
  • Although aggressive surgery is essential for the cure of osteosarcoma, its necessity in the treatment of Ewing sarcomas remains controversial.
  • [MeSH-minor] Adolescent. Adult. Cause of Death. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease Progression. Female. Fibrosarcoma / surgery. Histiocytoma, Benign Fibrous / surgery. Hospitals, Pediatric. Humans. Infant. Male. Mandibular Neoplasms / surgery. Maxillary Neoplasms / surgery. Neoplasm Recurrence, Local / pathology. Osteosarcoma / surgery. Radiotherapy, Adjuvant. Retrospective Studies. Sarcoma, Ewing / surgery. Survival Rate. Tennessee. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10813731.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / CA-23099
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  •  go-up   go-down


25. Wang H, Wan YX, Zhang QK: [Significance and expression of insulin-like growth factor 1 and IGF binding protein 3 in serum of patients with lung cancer]. Ai Zheng; 2004 Jun;23(6):710-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Seventy-eight cases with lung cancer (A group), 35 with benign pulmonary disease (B group), and 14 healthy controls (C group) were included in this study.
  • RESULTS: Serum IGF(1) level and IGF(1)/IGFBP(3) ratio in A group [X+/-S,(570.67+/-185.80) microg/L,(0.23+/-0.16)] were significantly higher compared with those of B group[(466.53+/-142.42) microg/L,(0.14+/-7.12E-02)] and those of C group [(427.66+/-141.19) microg/L,(0.12+/-8.2E-02)].
  • For the cases with lung cancer in pre-chemotherapy, the serum IGF(1) level was higher in patients with lymphoid node metastasis, and IGFBP(3) level of them was significantly lower than those without metastasis(P< 0.05).
  • Serum IGFBP(3) levels were lowest in the patients with bone metastases [(1933.14+/-715.21) microg/L, P< 0.05].
  • Fourteen post-chemotherapy patients showed a lower IGF(1) [(480.29+/-117.93)microg/L] than those in pre-chemotherapy[(661.76+/-153.54)microg/L](P< 0.05),whereas IGFBP(3) level was in inverse to IGF(1).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Female. Humans. Lung Diseases / blood. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15191678.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 3; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


26. Silva AL, Tomé MJ, Correia AE, Passos-Coelho JL: Human mammaglobin RT-PCR assay for detection of occult breast cancer cells in hematopoietic products. Ann Oncol; 2002 Mar;13(3):422-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human mammaglobin RT-PCR assay for detection of occult breast cancer cells in hematopoietic products.
  • (ii) to determine the incidence of tumor cell contamination of hematopoietic samples from patients with breast cancer.
  • MATERIALS AND METHODS: A nested RT-PCR assay for mammaglobin was developed.
  • Sensitivity was determined by serial dilution assays with breast cancer cell lines, human breast cancers and normal breast tissue.
  • Specificity was evaluated in hematopoietic samples from healthy volunteers and patients with hematological malignancies or solid tumors other than breast cancer.
  • RESULTS: The mammaglobin transcript was detected in all 15 breast cancers, one benign breast tumor and five normal breast tissues studied, as well as in three breast cancer cell lines, in dilutions as low as 10(-8).
  • The transcript was not detected in any of 47 peripheral blood samples, 15 bone marrow aspirates and 28 peripheral blood progenitor cell samples from the three control populations.
  • Mammaglobin mRNA was detected in 19 of 78 peripheral blood samples from patients with breast cancer starting systemic chemotherapy, as well as in five of 30 repeat samples collected before the fourth cycle of treatment.
  • The transcript was also present in six of seven bone marrow aspirates from patients with metastatic disease, two of five with loco-regional disease, but not in the aspirate of two patients with thrombocytopenia and a previous history of breast cancer.
  • CONCLUSIONS: Human mammaglobin mRNA is a sensitive and specific marker of breast cancer cells and should be further studied as a molecular marker of tumor cell contamination of hematopoietic tissues.

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11996474.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


27. Sommer J, Itani DM, Homlar KC, Keedy VL, Halpern JL, Holt GE, Schwartz HS, Coffin CM, Kelley MJ, Cates JM: Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma. J Pathol; 2010 Apr;220(5):608-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma.
  • Currently there is no effective chemotherapy for chordoma.
  • Recent studies report co-expression of insulin-like growth factor-1 receptor (IGF1R) and its cognate ligand in chordoma, but it is unknown whether this receptor tyrosine kinase is activated in these tumours.
  • Another gene in this region, methylthioadenosine phosphorylase (MTAP), is an essential enzyme of the purine salvage pathway and has therapeutic relevance because MTAP-deficient cells are particularly sensitive to inhibitors of de novo purine synthesis.
  • We investigated whether these pathways might be potential therapeutic targets for chordoma.
  • Paraffin-embedded tissue samples from 30 chordomas were analysed by immunohistochemistry for expression of the phosphorylated isoforms of IGF1R or the insulin receptor (pIGF1R/pIR) and selected downstream signalling molecules, including BCL2-associated agonist of cell death protein (BAD).
  • Skeletal chondrosarcomas, benign notochordal cell tumours, and fetal notochord were studied for comparison.
  • Phosphorylated IGF1R/IR was detected in 41% of chordomas, together with activated downstream signalling molecules, and pIGF1R/pIR was absent in benign notochordal cell tumours and fetal notochord.
  • Patients with pIGF1R/pIR-positive tumours showed significantly decreased median disease-free survival in multivariate survival analysis (p = 0.036), whereas phosphorylation of BAD at serine-99 was found to be associated with a favourable prognosis (p = 0.002).
  • Aberrant signalling cascades and disrupted metabolic pathways such as these may represent opportunities for novel targeted therapeutic approaches for the treatment of chordoma.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Chordoma / metabolism. Purine-Nucleoside Phosphorylase / metabolism. Receptor, IGF Type 1 / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Neoplasms / metabolism. Bone Neoplasms / pathology. Child. Child, Preschool. Chondrosarcoma / metabolism. Chondrosarcoma / pathology. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Female. Humans. Male. Middle Aged. Neoplasm Proteins / metabolism. Notochord / metabolism. Phosphorylation. Prognosis. Signal Transduction. Survival Analysis. Tissue Array Analysis. Young Adult

  • Genetic Alliance. consumer health - Chordoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20140939.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Grant] United States / BLRD VA / BX / I01 BX000458
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Neoplasm Proteins; EC 2.4.2.1 / Purine-Nucleoside Phosphorylase; EC 2.4.2.28 / 5'-methylthioadenosine phosphorylase; EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


28. Weber K, Damron TA, Frassica FJ, Sim FH: Malignant bone tumors. Instr Course Lect; 2008;57:673-88
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant bone tumors.
  • Malignant bone tumors represent a small percentage of cancers nationwide and also are much less common than malignant soft-tissue tumors.
  • The rarity of the condition makes it imperative that orthopaedic surgeons in nononcologic practices are able to recognize the symptoms that suggest a possible bony malignancy to avoid inappropriate or delayed treatment.
  • The most common primary malignant bone tumors, osteosarcoma and Ewing's sarcoma, occur in childhood.
  • Rare tumors such as chordoma and adamantinoma have anatomic predilections for the sacrum and tibia, respectively.
  • The primary symptom of a patient with a malignant bone tumor is pain, which often occurs at rest or at night.
  • Patients with a likely malignancy require thorough staging to determine the extent of disease and a well-planned biopsy for accurate diagnosis.
  • Knowledge of specific tumor characteristics and treatment options for osteosarcoma, Ewing's sarcoma, chondrosarcoma, malignant fibrous histiocytoma, chordoma, and adamantinoma is important.
  • Patients with osteosarcoma and resectable Ewing's sarcoma are treated with chemotherapy followed by surgical resection.
  • Secondary sarcomas can occur in previously benign bone lesions and require aggressive treatment.
  • Specific techniques are available for the resection of malignant bone tumors from the upper extremities, lower extremities, pelvis, and spine.
  • The care of patients with primary malignant bone tumors requires a multidisciplinary approach to treatment.
  • [MeSH-major] Bone Neoplasms. Orthopedic Procedures / methods
  • [MeSH-minor] Global Health. Humans. Morbidity. Neoplasm Staging / methods. Prognosis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18399615.001).
  • [ISSN] 0065-6895
  • [Journal-full-title] Instructional course lectures
  • [ISO-abbreviation] Instr Course Lect
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


29. Klenke FM, Merkle T, Fellenberg J, Abdollahi A, Huber PE, Gebhard MM, Ewerbeck V, Sckell A: A novel model for the investigation of orthotopically growing primary and secondary bone tumours using intravital microscopy. Lab Anim; 2005 Oct;39(4):377-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel model for the investigation of orthotopically growing primary and secondary bone tumours using intravital microscopy.
  • Here is reported the development of an experimental model using intravital microscopy as a tool to orthotopically investigate malignant bone tumours.
  • Although up to 85% of the most frequently occurring malignant solid tumours, such as lung and prostate carcinomas, metastasize into the bone, and despite the knowledge that a tumour's course may be altered by its surrounding tissue, there is no adequate experimental model available enabling the investigation of orthotopically grown bone tumours in vivo.
  • Intravital microscopy is an internationally accepted experimental method, used in various acute and chronic animal models, that enables qualitative and quantitative analysis of the angiogenesis, microcirculation, growth behaviour, etc. of various benign and malignant tissues.
  • Additionally, tissue samples can be taken after termination of the in vivo experiments for further ex vivo investigation (histology, immunohistochemistry, molecular biology, etc.
  • Severe combined immunodeficient mice were fitted with a cranial window preparation where the calvaria served as the site for orthotopic implantation of the solid human tumours Saos-2 osteosarcoma (primary) and A 549 lung carcinoma and PC-3 prostate carcinoma (secondary).
  • Histological assessment confirmed the data obtained in vivo, showing typical tumour growth with infiltration of the surrounding osseous and soft tissues.
  • This novel model serves as a valuable tool in understanding the biology of primary and secondary bone tumours in physiological and pathophysiological situations, with implications for the most areas of tumour therapy such as chemotherapy, radiation and antiangiogenesis.
  • [MeSH-major] Bone Neoplasms / pathology. Osteosarcoma / pathology
  • [MeSH-minor] Animals. Lung Neoplasms / pathology. Male. Mice. Mice, SCID. Microscopy, Fluorescence. Microscopy, Video. Neoplasm Transplantation. Neovascularization, Pathologic / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16197704.001).
  • [ISSN] 0023-6772
  • [Journal-full-title] Laboratory animals
  • [ISO-abbreviation] Lab. Anim.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


30. Knoeller SM, Uhl M, Adler CP, Herget GW: Differential diagnosis of benign tumors and tumor-like lesions in the spine. Own cases and review of the literature. Neoplasma; 2004;51(2):117-26
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of benign tumors and tumor-like lesions in the spine. Own cases and review of the literature.
  • Although benign tumors and tumor-like lesions of the spine are shown in every orthopedic teaching book, it is often surprising how little attention is paid to the differential diagnosis and diagnostic investigations, respectively, since surgical treatment and postoperative control depends on exact diagnosis.
  • Bone deviations are diagnosed radiologically.
  • Different types of benign bone tumors and tumor-like lesions of the spine including osteochondroma, osteoblastoma, osteoid osteoma, aneurysmal bone cyst, eosinophilic granuloma, hemangioma, and giant cell tumor, their appearance relation to the age and location in the spine were reviewed and the common histologic subtypes described.
  • Treatment including radiation, chemotherapy and the surgical procedure as well as the postoperative treatment of patients with benign tumors and tumor-like lesions of the spine are discussed.
  • [MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / pathology. Spine / pathology
  • [MeSH-minor] Adult. Back Pain. Biopsy, Needle. Child. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15190421.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  •  go-up   go-down


31. Lamprecht P, Lerin-Lozano C, Merz H, Dennin RH, Gause A, Voswinkel J, Peters SO, Gutzeit O, Arlt AC, Solbach W, Gross WL: Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis; 2003 Dec;62(12):1230-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To report the successful induction of remission with the monoclonal anti-CD20 antibody rituximab in a patient with hepatitis C virus (HCV) associated cryoglobulinaemic vasculitis and a non-Hodgkin's lymphoma (NHL) resistant to previously advocated conventional treatments.
  • At this stage the disease was refractory to interferon alpha2b and ribavirin and to subsequent immunosuppressive treatment with cyclophosphamide.
  • Bone marrow biopsy disclosed absence of the NHL.
  • CONCLUSIONS: Transition of the underlying "benign" lymphoproliferative disease to a malignant lymphoma may result in difficult to treat HCV associated cryoglobulinaemic vasculitis.
  • Rituximab offers a new possibility for inducing remission in refractory HCV associated cryoglobulinaemic vasculitis and the lymphoproliferative disorder.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Cryoglobulinemia / drug therapy. Hepatitis C, Chronic / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Vasculitis / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antiviral Agents / therapeutic use. Drug Resistance, Neoplasm. Drug Resistance, Viral. Female. Humans. Interferon-alpha / therapeutic use. Middle Aged. Recombinant Proteins. Remission Induction. Ribavirin / therapeutic use. Rituximab

  • Genetic Alliance. consumer health - Vasculitis.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Vasculitis.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14644867.001).
  • [ISSN] 0003-4967
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 49717AWG6K / Ribavirin; 4F4X42SYQ6 / Rituximab; 99210-65-8 / interferon alfa-2b
  • [Other-IDs] NLM/ PMC1754408
  •  go-up   go-down


32. Yashi M, Nukui A, Kurokawa S, Ochi M, Ishikawa S, Goto K, Kobayashi Y, Muraishi O, Tokue A: Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer. Prostate; 2003 Sep 1;56(4):305-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer.
  • BACKGROUND: The neuroendocrine (NE) pathway has been attracting attention as a mechanism for the androgen-independent progression because the neuropeptide provokes tumor growth and inhibits apoptosis under androgen-deprived milieu in prostate cancer cells.
  • METHODS: Serum ProGRP status was determined with an enzyme-linked immunosorbent assay (ELISA) in 460 men with benign and malignant prostatic diseases, chronic renal failure, and healthy controls.
  • Seventy patients with metastatic prostate cancer including four patients (5.7%) with NE carcinoma who underwent hormonal therapy were enrolled in the prognostic analyses by Cox proportional hazards model.
  • Multivariate analysis demonstrated that PS, serum ProGRP, and nadir PSA held an independent predictive value for PFS (P < 0.05), and all correlated with bone-related factors.
  • Serum ProGRP was the most significant predictor among pre-treatment factors in this model (P = 0.0094).
  • CONCLUSIONS: The neuropeptide precursor ProGRP is a distinct serum marker that is useful to know the NE milieu and provides prognostic information in patients with advanced prostate cancer.
  • Standard therapy for metastatic prostate cancer may make progress when further studies will clarify the causative link between serum ProGRP level and androgen-independent disease progression.
  • [MeSH-major] Biomarkers, Tumor / analysis. Gastrointestinal Hormones / analysis. Neoplasm Metastasis. Neoplasm Staging / methods. Peptide Fragments / analysis. Peptides / analysis. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / pathology. Recombinant Proteins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Androgens / pharmacology. Antineoplastic Agents, Hormonal / pharmacology. Drug Resistance, Neoplasm. Enzyme-Linked Immunosorbent Assay. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Prostate-Specific Antigen / analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 12858359.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Gastrointestinal Hormones; 0 / Peptide Fragments; 0 / Peptides; 0 / Recombinant Proteins; 0 / pro-gastrin-releasing peptide (31-98); EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down






Advertisement